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Tavoitteet:
Tämän tutkimuksen tavoitteena oli selvittää, miten veressä ilmentyvien geenien sekä niiden
muodostamien signalointireittien aktiivisuus eroaa niillä prediabeetikoilla, joilla on
samanaikaisesti dyslipidemia verrattuna niihin prediabeetikoihin, joilla dyslipidemiaa ei ole,
sekä verrata näitä ryhmiä normaalit sokeri- ja rasva-arvot omaavaan kontrolliryhmään.
Menetelmät ja tulokset:
Tutkimusaineistoon kuului 1 240 Lasten sepelvaltimotaudin riskitekijät -tutkimukseen vuonna
2011 osallistunutta henkilöä, jotka olivat tuolloin iältään 34–49-vuotta. Signalointireittien
aktiivisuus analysoitiin GSEA (Gene set enrichment analysis) -ohjelman avulla. Niillä
henkilöillä, joilla oli prediabetes mutta ei dyslipidemiaa, kolesterolisynteesin sekä tiettyjen
CD8-lymfosyytti- ja interleukiini-12-välitteisten reittien aktiivisuus oli kontrolliryhmään
verrattuna tilastollisesti merkittävästi lisääntynyt. Vastaavia muutoksia ei havaittu niillä
tutkittavilla, joilla oli samanaikaisesti sekä prediabetes että dyslipidemia. Verrattaessa näitä
kahta prediabeetikkoryhmää keskenään reittien säätelyssä ei ollut tilastollisesti merkittäviä
eroja. Yksittäisten geenien ilmentymisessä oli vain lieviä eroja.
Johtopäätökset:
Sekä prediabetes että dyslipidemia vaikuttavat verisolujen geeniekspressioon. Tulosten
kliinistä merkitystä esimerkiksi sydän- ja verenkiertoelimistön sairauksiin liittyen voi olla
tarpeellista selvittää seurantatutkimuksissa.
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Abstract 
BACKGROUND: Prediabetes (PR) often occurs together with dyslipidaemia (D), which is 
paradoxically treated with statins predisposing to type 2 diabetes mellitus. We examined 
peripheral blood pathway profiles in prediabetic subjects with (PRD) and without 
dyslipidaemia (PR0) and compared these to non-prediabetic controls (C) without 
dyslipidaemia (C0). 
METHODS: The participants were from the Cardiovascular Risk in Young Finns Study, 
including 1,240 subjects aged 34-49 years. Genome-wide expression data of peripheral blood 
and gene set enrichment analysis were used to investigate the differentially expressed genes 
and enriched pathways between different subtypes of prediabetes.  
RESULTS: Pathways for cholesterol synthesis, interleukin-12 (IL12)-mediated signalling 
events and downstream signalling in naïve CD8+ T cells were up-regulated in the PR0 group 
in comparison to controls (C0) and the up-regulation of these pathways was independent of 
waist circumference, blood pressure, smoking status and insulin.  Adjustment for CRP left the 
CD8+ T cell signalling and IL12-mediated signalling event pathway up-regulated. The 
cholesterol synthesis pathway was also up-regulated when all prediabetic subjects (PR0 and 
PRD) were compared to the non-prediabetic control group. No pathways were up- or down-
regulated when the PRD group was compared to the C0 group. Five genes in the PR0 group 
and one in the PRD group was significantly differentially expressed in comparison to the C0 
group. 
CONCLUSIONS: Blood cell gene expression profiles differ significantly between 
prediabetic subjects with and without dyslipidaemia. Whether this classification may be used 
in detection of prediabetic individuals at a high risk of cardiovascular complications remains 
to be examined. 
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Abbreviations: BH-FDR, Benjamini-Hochberg false discovery rate; BP, blood pressure; C0, 
normoglycaemic and normolipidaemic subjects; CD, normoglycaemic and dyslipidaemic 
subjects; CV, cardiovascular; FDR, false discovery rate; FWER, family-wise error rate; 
GSEA, gene set enrichment analysis; IFG, impaired fasting glucose; IGT, impaired glucose 
tolerance; KEGG, Kyoto Encyclopedia of Genes and Genomes; NCI PID, National Cancer 
Institute Pathway Interaction Database; NES, normalised enrichment score; PC, principal 
component; PR0, prediabetic and normolipidaemic subjects; PRD, prediabetic and 
dyslipidaemic subjects; TC, total cholesterol; TG, triglycerides; T1DM, type 1 diabetes 
mellitus; T2DM, type 2 diabetes mellitus; YFS, Young Finns Study. 
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Introduction 
The prevalence of type 2 diabetes mellitus (T2DM) and the subsequent development of its 
cardiovascular complications (CV) are increasing worldwide. A potential risk factor for the 
development of T2DM is prediabetes (PR), which may be defined as an intermediate state 
between normal glucose metabolism and T2DM. The American Diabetes Association defines 
prediabetes as impaired glucose tolerance (IGT), impaired fasting glucose (IFG) or elevated 
HbA1c 
1. Deficiency in the insulin secretion of pancreatic beta cells has a more pronounced 
role in prediabetes than insulin resistance 2, but most persons with prediabetes are also 
insulin-resistant 3. 
Dyslipidaemia, which is defined by elevated total cholesterol (TC), LDL 
cholesterol (LDL-C), non-HDL cholesterol (non-HDL-C) or triglycerides (TG), or low HDL 
cholesterol (HDL-C), 4 commonly occurs together with T2DM. A typical pattern of lipid 
abnormalities in diabetic patients includes hypertriglyceridaemia, low HDL-C and a presence 
of small dense LDL-C particles 5. The same pattern, known as atherogenic dyslipidaemia, has 
been shown to occur already during the prediabetic stage 6,7. Metabolically, low absorption 
efficiency and high synthesis of cholesterol are also related to an elevated serum glucose 
level and insulin resistance 8,9. However, whether the progression or development of CV 
complications will differ in prediabetic patients with and without dyslipidaemia is not well 
known.  
In atherogenic dyslipidaemia, statins are widely used as first-line drugs. Since 
the treatment goal for serum LDL-C is more stringent in patients with T2DM than in those 
without T2DM, high-dose statin treatment may be needed 4. The use of statins in prediabetic 
subjects may be complicated, since these drugs can increase the risk of incident T2DM 10, 
and by affecting insulin sensitivity, insulin secretion and glucose transport increase plasma 
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glucose levels 11. Despite this controversy, statins yield an overall benefit in terms of 
preventing vascular events and, therefore, these drugs are widely recommended in current 
treatment guidelines also for the treatment of dyslipidaemia in T2DM patients 4. With this 
clinical background, it is rational to seek better understanding of the metabolic differences of 
PR subphenotypes with and without dyslipidaemia. 
Gene expression and pathway profiling of blood and tissue samples may 
provide better understanding of the pathogenesis of prediabetes and its association to 
dyslipidaemia. An earlier metabolomics investigation of plasma from non-diabetic subjects 
with reduced insulin sensitivity showed alterations in lipid metabolic pathways, steroid 
hormone biosynthesis and bile acid metabolism 12. The majority of these pathways and 
certain amino acid metabolism pathways have also been found to be differentially regulated 
in the liver of pigs with impaired incretin (a group of metabolic hormones that stimulate a 
decrease in blood glucose levels) function 13. Altered pathways in lipid metabolism, insulin 
action, inflammatory response and complex oxidative processes have also been revealed from 
subcutaneous adipose and muscle tissue from non-diabetic, insulin-resistant subjects 14,15. 
However, these earlier metabolic studies did not take into account whether plasma lipid 
abnormalities were present in the subjects. 
It has been suggested that insulin resistance elicits dyslipidaemia either 
mechanically or by means of genetic linkage, but further validation is still needed 2,3. We 
aimed to identify the metabolic pathways and gene expression associated with the prediabetic 
state, with special respect to a division based on the subjects’ dyslipidaemia status. In order to 
pinpoint dysregulated metabolic pathways associated with these PR subphenotypes, we 
performed a gene set enrichment pathway analysis (GSEA) and also otherwise analysed 
gene-wise differences between PR subphenotypes and controls. 
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Materials and Methods 
Population 
The Cardiovascular Risk in Young Finns Study (YFS) is a Finnish longitudinal population 
study on the evolution of cardiovascular risk factors from childhood to adulthood, the sample 
and methods have been described in detail elsewhere 16,17. The present study included 1,240 
subjects who were not diagnosed with T1DM or T2DM (in 2012), were not on medication for 
hypertension or hypercholesterolaemia and for whom complete gene expression data as well 
as data on lipids, glucose and clinical characteristics were available. 
The study plan was approved by the ethics committees of all participating 
universities, and the study protocol of each study phase corresponded with the proposal by 
the World Health Organization. All subjects gave written informed consent, and the study 
was conducted in accordance with the Declaration of Helsinki. 
Clinical and biochemical measurements 
Height and weight were measured and body mass index (BMI) was calculated as weight in 
kilograms divided by height in metres squared. Waist circumference was measured using an 
anthropometric tape at the midpoint between the iliac crest and the lowest rib to the nearest 
0.1 cm. Blood pressure was measured three times after a 5-min rest with a random zero 
sphygmomanometer and was estimated as the average of the three measurements.  
Venous blood samples were drawn after an overnight fast for the determination 
of serum lipid levels, glucose, insulin, glycated haemoglobin A1c (HbA1c) and high-sensitive 
C-reactive protein (hs-CRP). Standard enzymatic methods were used for serum TC, TG and 
HDL-C determinations. LDL-C was calculated by the Friedewald formula in participants 
with TG levels < 4.0 mmol/l 18. Non-HDL-C was calculated as TC – HDL-C. Glucose 
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concentrations were determined by the enzymatic hexokinase method. Serum insulin was 
measured with immunoassay and HbA1c with an immunoturbidimetric method. Hs-CRP was 
determined immunoturbidimetrically. Details of all of the methods have been previously 
described elsewhere 19. 
RNA isolation, microarrays and data processing 
RNA was isolated and the gene expression levels were analysed using commercially 
available kits. Expression data was analysed in R (http://www.r-project.org/) using the 
Bioconductor packages (http://www.bioconductor.org/). Details of the process have been 
previously described elsewhere 20. 
Definition of prediabetes and dyslipidaemia 
The classification of prediabetes was based on fasting plasma glucose and HbA1c according 
to the criteria of the American Diabetes Association 1. People with impaired IFG, i.e. 
prediabetes, were defined as having a fasting plasma glucose level of 5.6–6.9 mmol/l or 
HbA1c of 5.7–6.4% (38–46 mmol/l) and not diagnosed with T2DM. The diagnosis of T2DM 
included subjects with a fasting plasma glucose level of over 7.0 mmol/l or HbA1c of over 
6.5% (48 mmol/l), or those with reported use of oral glucose-lowering medication or insulin 
(but had not reported having T1DM) or who had a reported diagnosis of T2DM by a 
physician.  
Dyslipidaemia was defined according to the European guidelines 21. The criteria 
for dyslipidaemia were TC > 5.0 mmol/l, LDL-C > 3.0 mmol/l, HDL-C < 1.0 mmol/l in men 
and < 1.2 mmol/l in women, non-HDL-C > 3.8 mmol/l or TG > 1.7 mmol/l. 
Statistical analysis 
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Gene sets were collected from five publicly available collections: BioCarta 
(http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways), KEGG (Kyoto Encyclopedia of 
Genes and Genomes, http://www.genome.jp/kegg/), Reactome (http://www.reactome.org/), 
NCI PID (National Cancer Institute Pathway Interaction Database, http://pid.nci.nih.gov/) 
and HumanCyc (http://humancyc.org/). Enrichment analysis was performed by using each 
gene set separately. In order to avoid too narrowly or too broadly defined functional gene 
sets, pathways containing less than 10 or more than 200 genes were excluded. As a result, 
1,078 pathways were included in the study. The reduced number of pathways potentially 
increases the power of the analysis by decreasing the multiple testing correction burden. 
The study population was divided into four subphenotypes as follows: 
prediabetic individuals with (PRD) or without dyslipidaemia (PR0), and normoglycaemic 
(non-prediabetic) control (C) subjects with (CD) or without (C0) dyslipidaemia. All 
prediabetic subjects (PR), regardless of dyslipidaemia status, were compared to the non-
prediabetic control group (C0 and CD together). The PR0 and PRD groups were individually 
compared to the C0 group and also to each other (PR0 vs. PRD). We also did similar analyses 
and examined whether the results differ when the dyslipidaemia status definition was based 
on the high LDL-C level (LDL > 3.0 mmol/l) only. The baseline characteristics of the groups 
were compared using the t-test for continuous variables and a χ2 test for proportions. 
Potential population stratification was taken into account by using principal 
components (PCs) computed from all genotypes as covariates 22. Based on a scree plot, the 
seven first PCs were used. In addition to the PCs, the analyses were adjusted by age, sex, 
BMI or waist circumference, smoking, insulin, systolic and diastolic blood pressure, and hs-
CRP. R language was used for adjusting the gene expression data. After the adjustment, 
GSEA software (http://www.broad.mit.edu/gsea) 23,24 was used to analyse the association of 
gene pathways with the phenotype. The pathways were considered to be significantly up- or 
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down-regulated when the false discovery rate (FDR) was smaller than 0.10 and the family-
wise error rate (FWER) was smaller than 0.05 after 1,000 permutation cycles. FDR < 0.25 
can be considered significant according to the criteria recommended by Subramanian et al. 23.  
The expression of individual genes in the same setting was analysed using the 
phenoTest R package with a Benjamini-Hochberg-FDR-corrected p-value of ≤ 0.05 and log2 
fold change of ≥ 1.5 as the significance level. The analysis was adjusted with age, sex, BMI 
and the first seven PCs. For boxplots, the statistical significance of the difference in gene 
expression was assessed using the nonparametric Wilcoxon signed-rank test. 
Results 
The demographics of the study population, when the division is based on any type of 
dyslipidaemia, or hypercholesterolaemia defined as a high LDL cholesterol (LDL > 3.0 
mmol/l) only, are presented in Table 1. Of the non-medicated subjects with prediabetes, 
79.5% had dyslipidaemia and 66.0% hypercholesterolaemia defined as LDL > 3.0 mmol/l. 
When comparing all PR individuals to the non-prediabetic control group (C), GSEA 
identified up-regulation of cholesterol biosynthesis pathways in all of the used but differently 
adjusted models 1–3 (FDR < 0.014 for all) (Table 2). A positive normalized enrichment score 
(NES) indicated that all the pathways were up-regulated. The leading-edge subsets containing 
the most up-regulated genes are almost identical in the KEGG steroid and HumanCyc 
cholesterol biosynthesis pathways (Supplementary table 1). In the PR vs. C group 
comparison, superpathway of methionine degradation remained significantly enriched in 
models 1 and 2 (FDR < 0.006 and < 0.015, respectively). However, in model 3, the additional 
adjustment with hs-CRP abolished the association.  
Two additional pathways, cholesterol biosynthesis II (via 24,25-
dihydrolanosterol) and cholesterol biosynthesis III (via desmosterol) from HumanCyc, were 
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closely and significantly co-enriched with the cholesterol biosynthesis pathway because they 
all share the same genes. Hence, they are not shown in the tables. 
These KEGG and HumanCyc pathways were also up-regulated when the PR0 
group was compared to the corresponding control group without prediabetes and 
dyslipidaemia (C0) after adjustment for age, sex, BMI and the first seven PCs (Table 3). In 
addition, in this setting, the pathways for interleukin (IL)-12-mediated signalling events and 
downstream signalling in naive CD8+ T cells were also significantly up-regulated. When 
further adjusted for waist circumference (instead of BMI), blood pressure, smoking and 
insulin, all other pathways except the HumanCyc superpathway of cholesterol synthesis 
remained significant. In the fully adjusted model 3, the association of steroid and cholesterol 
biosynthesis pathways was abolished after additional adjustment for hs-CRP, leaving only the 
downstream signalling in naive CD8+ T cells and IL12-mediated signalling events 
significantly up-regulated. 
When the PRD group was compared to the C0 group, no pathways were 
significantly enriched in any of the models. In the PR0 vs. PRD group comparison one 
Reactome pathway, Cytochrome P450 – arranged by substrate type was up-regulated in the 
PRD group (NES 2.09, p < 0.001, FDR 0.041, FWER 0.026) after adjustment for age, sex, 
BMI and the seven first PCs. Further adjustment in models 2 and 3, similar as in other 
analyses, abolished the association.  
When comparing prediabetic subjects with normal LDL-C (< 3.0 mmol/l) 
(PRNC) to normoglycaemic subjects with normal LDL-C (CNC), one pathway for cholesterol 
biosynthesis remained  significantly up-regulated in all models 1–3 (Table 4). In prediabetic 
subjects with high LDL-C (≥ 3.0 mmol/l) (PRHC), no pathways were significantly enriched as 
compared to the CNC group. When comparing the two prediabetic groups to each other (PRNC 
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vs. PRHC), one pathway from NCI PID was significantly up-regulated. Regulation of 
cytoplasmic and nuclear SMAD2/3 signalling was enriched in the PRHC group in models 1 
(NES 2.03, p 0.002, FDR 0.029, FWER 0.022) and 2 (NES 2.00, p<0.001, FDR 0.042, 
FWER 0.033) but not in model 3.  
The expression of individual pathway genes was not statistically significant in 
any PR phenotype when compared to the C0 group. This is explained by the fact that GSEA 
considers all expressed genes by rank without a fold-change threshold. Therefore, we also 
tested gene-wise differences between PR subphenotype groups with a less stringent cut-off 
value for log2 fold change (FC >1.2) and a Benjamini-Hochberg-FDR-corrected p-value of ≤ 
0.05 (Supplementary table 2). In gene-wise analysis, we identified five genes up-regulated 
in the PR0 group as compared to the C0 group, including type 1 neurotrophic tyrosine kinase 
receptor (NTRK1); granzyme B (GZMB); perforin 1 (PRF1); killer cell immunoglobulin-like 
receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4); and family with sequence 
similarity 179 member A (FAM179A). One gene, secretory leukocyte peptidase inhibitor 
(SLPI), was up-regulated in the PRD subjects as compared to the C0 group. The trend analyses 
for these six genes are shown in Figure 1. In PR vs. C, PR0 vs. PRD and PRNC vs. PRHC group 
comparisons no genes were differentially expressed. 
Discussion 
Our analysis of peripheral blood cell mRNA expression shows, for the first 
time, that the pathway profiles differ significantly between prediabetic subphenotypes with 
and without dyslipidaemia. We observed that, compared to normoglycaemic and 
normolipidaemic controls, the cholesterol biosynthesis pathway was up-regulated in 
normolipidaemic prediabetic individuals but not in those with both prediabetes and 
dyslipidaemia. Also, pathways related to the immune response were up-regulated only in the 
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PR0 group. It is not surprising that pathway analysis identified differences between 
prediabetic subphenotypes. However, using the most recent pathway databases our analysis 
pinpointed the specific pathways which were up-regulated. 
The enrichment of the cholesterol biosynthesis pathway was independent of 
both BMI and waist circumference. Parallel results have been reported by Gylling et al. 9 who 
assayed cholesterol precursors and markers of cholesterol synthesis and absorption from 
plasma. In their study, markers of cholesterol synthesis were already increased in subjects 
with IFG, and cholesterol metabolism was regulated more by peripheral insulin sensitivity 
than obesity. In the present study, the enrichment remained significant until the analysis was 
adjusted for hs-CRP. This suggests that an up-regulated cholesterol biosynthesis pathway is 
related to the increased overall inflammation as measured by hs-CRP. Interestingly, serum 
hs-CRP concentration has been previously associated with dietary cholesterol absorption but 
not synthesis of cholesterol in subjects with IFG or IGT and features of the metabolic 
syndrome cholesterol metabolism 25. 
The mechanism through which prediabetes in the absence of dyslipidaemia 
regulates cholesterol metabolism gene pathways in blood cells remains open. A possible 
reason for the up-regulation of cholesterol synthesis in the PR0 group is the cholesterol 
deprivation inside the blood cells due to the lack of extra cholesterol available in the plasma. 
In leukocytes, the expression of certain genes which are included in the KEGG Steroid 
biosynthesis pathway has been found to be associated with plasma lipid levels. The 
expression is hypothesized to be activated by peroxisome proliferative activated receptors 
(PPARs). 26 However, we did not observe changes in the expression of PPARs. Also, we did 
not observe gene-wise changes in the expression of HMG-CoA reductase (HMGCR), the 
rate-limiting step in cholesterol metabolism or sterol-regulatory element-binding protein 
(SREBP-2), which regulates the transcription of HMGCR. The upregulated pathways consist 
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of the latter half of the cholesterol biosynthesis pathway, with farnesyl pyrophosphate being 
the first intermediate. The first sterol intermediate is lanosterol, and the subsequent reactions 
define the post-squalene part of the pathway. In this portion of the pathway, the 
demethylation of lanosterol has been suggested to act as the rate-limiting step 27.  
Since isolated IFG and IGT are characterised by different patterns of lipid 
changes 28, they presumably affect the lipid metabolism by distinct mechanisms. The down-
regulation of the cholesterol biosynthesis pathway has been previously associated in insulin 
resistance in adipose tissue 14, but in our study, the same pathway was up-regulated in 
peripheral blood. Analogous results have been published related to the mitogen-activated 
protein kinase (MAPK) signalling pathway in insulin resistance in metabolic syndrome – the 
pathway is up-regulated in muscle tissue but down-regulated in blood 29,30. On the other hand, 
one study has demonstrated that the mechanisms which regulate gene expression in liver and 
mononuclear leukocytes are similar and that these leukocytes can be used to predict the level 
of expression of HMGCR and LDL receptor (LDLR) genes 31. This could indicate that also 
the hepatic cholesterol production is increased in the PR0 group, although we did not observe 
increased expression of these two genes.  
Recent data suggests that non-alcoholic fatty liver disease (NAFLD) results 
mainly from disturbed hepatic cholesterol homeostasis and the hepatic accumulation of free 
cholesterol 32. If the cholesterol synthesis pathway is up-regulated in the liver, the newly 
synthesized cholesterol may promote the pathogenesis of NAFLD, since cholesterol export 
and bile acid synthesis pathways were not up-regulated. This hypothesis is supported by a 
Japanese study that showed a positive association between NAFLD and IFG, independently 
of T2DM risk factors 33. NAFLD is also considered to be a consequence of insulin resistance 
34, but it is also an independent risk factor of T2DM, particularly in individuals with IFG 35. 
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Based on above reasons, potentially increased hepatic cholesterol production 
would imply that the onset of prediabetes launches a cascade leading to 
hypercholesterolaemia and/or NAFLD, which highlights the importance of early detection of 
prediabetes and prevention of T2DM through lifestyle intervention. Guidelines in condensed 
form have been provided for building up an effective intervention program, the IMAGE 
toolkit 36 gives also instructions for evaluation and quality assurance. In addition to working 
at the patient level, actions at policy and environmental levels are needed for sustainable 
diabetes prevention 37.  
The enrichment of the IL12 signalling pathway remained significant in all 
models when the PR0 group was compared to the C0 group. Elevated IL12 levels have been 
previously shown to be dependent on hs-CRP 38 and peripheral insulin resistance 39 in T2DM. 
Since the IL12 pathway remained up-regulated when the analysis was adjusted with both 
serum insulin level and hs-CRP, it may be suggested that, in the PR0 group, the activation of 
the IL12 pathway is mediated by another mechanism. When only the LDL-C levels were 
taken into account, the pathway profiles were similar to the ones of all prediabetic subjects, 
i.e. when the dyslipidaemia status was not considered. This suggests that the up-regulation of 
IL12-mediated and CD8+ T cell pathways could be partly related to hypertriglyceridaemia or 
low HDL-C. 
The enrichment of cholesterol biosynthesis and inflammation related pathways 
was seen in the PR0 group when compared to the C0 group but not when compared to the PRD 
group, which implies that the metabolic differences between the two PR subphenotypes are 
small. However, whether this difference will evolve over time requires longitudinal studies. 
The analysis of individual genes revealed only a moderate increase in gene 
expression. Some of the genes have been previously associated with metabolic dysfunction. 
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Only one gene, secretory leukocyte protease inhibitor (SLPI) which is a potent inhibitor of 
the inflammatory cascade 40, was up-regulated in the PRD group. The up-regulation of SLPI 
has also been previously shown to correlate negatively with HDL cholesterol and positively 
with HbA1c. This may be due to an attempt to counterbalance the low-grade inflammation 
associated with prediabetes and dyslipidaemia. 41 The expression of LDLR or scavenger 
receptor genes 42 in the PR0 or PRD groups was not different compared to the C0 group. Since 
scavenger receptors are key molecules in the formation of atherosclerotic plaques 43, our 
results imply that prediabetes combined with dyslipidaemia does not directly cause 
atherosclerosis, which is also stated by Grundy 2. 
Three out of five genes that were slightly up-regulated in the PR0 group – 
granzyme B (GZMB); perforin 1 (PRF1); and killer cell immunoglobulin-like receptor, two 
domains, long cytoplasmic tail, 4 (KIR2DL4) – have been found to be down-regulated after 
exposure to high blood glucose in normoglycaemic controls. In T2DM patients, the 
expression levels of these genes has been reported to be low already and hardly affected by 
hyperglycaemia. 44 These genes are typically expressed in cells with cytotoxic functions, such 
as CD8+ T cells 45. GZMB and PRF1 are also included in the downstream signalling in the 
naive CD8+ T cells pathway, which was up-regulated in the PR0 group but not in the PRD 
group in comparison to the C0 group. The reason why GZMB, PRF1 and KIR2DL4 were up-
regulated in the PR0 group but not in the PRD group and expressed in lower levels in T2DM 
patients in the study by van der Pouw Kraan et al. 44 might be that one or more of the 
components of dyslipidaemia co-regulate the expression of these genes; the T2DM patients in 
their study 44 met the elevated triglycerides criterion of dyslipidaemia used in our study. 
However, in another study, the plasma level of granzyme B correlated positively with fasting 
glucose and HbA1c, as well as with triglycerides, total cholesterol and LDL cholesterol 46. 
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The present study has some limitations. A major one is that profiling gene 
expression from peripheral blood cells makes it challenging to speculate how the expression 
levels represent the gene expression in other tissues. Another limitation is that no glucose 
tolerance tests were performed on the study population and the definition of prediabetes was 
based only on fasting plasma glucose and HbA1c levels. Some studies 47,48, but not all 49, 
have shown that IGT is a better predictor of cardiovascular complications than IFG. This 
raises the question whether there are differences in gene expression and pathway profiles 
when prediabetes is diagnosed by either IFG or IGT. However, the HbA1c cut-off point for 
prediabetes has a high specificity to identify cases of IGT 1 and also subsequent 6-year 
diabetes incidence 50. In addition, the Finnish gene pool has been shown to be distinctive and 
the results may not be directly generalizable to populations with a different ethnic 
background. We also recognize that microarray studies are limited by multiple testing 
problems and false positives. 
In summary, our data indicates that blood cell gene expression pathway profiles 
differ significantly between prediabetic subphenotypes with and without dyslipidaemia. The 
pathway analysis identified up-regulated pathways, including cholesterol biosynthesis, IL12-
mediated signalling and signalling in naïve CD8+ T cells in prediabetic individuals only in 
the absence of dyslipidaemia. However, whether this classification may be used in e.g. early-
phase detection of individuals at a high risk of cardiovascular complications should be further 
examined in longitudinal studies. The clinical implication is that physicians should actively 
screen patients for prediabetes and dyslipidaemia and encourage especially those with 
prediabetes to permanent lifestyle changes with active follow-ups. 
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Table 1. Demographics of the study population according to prediabetes/control (PR/C), 
dyslipidaemia (D/0) and hypercholesterolaemia subtype status (HC/NC). 
 C0  PR0 CD PRD 
Number of subjects 256 79 598 307 
Age (years) 40.1 (4.87) 41.2 (5.00) 41.4 (5.07) a 42.4 (4.97) a 
Males (%) 26.2 41.8 a 42.0 a 63.8 a 
Total cholesterol (mmol/l) 4.36 (0.40) 4.33 (0.51) 5.42 (0.89) a 5.59 (0.89) a 
LDL cholesterol (mmol/l) 2.51 (0.35) 2.53 (0.43) 3.53 (0.76) a 3.63 (0.79) a 
HDL cholesterol (mmol/l) 1.49 (0.25) 1.40 (0.27) a 1.34 (0.35) a 1.25 (0.32) a 
Non-HDL cholesterol (mmol/l) 2.88 (0.36) 2.92 (0.49) 4.09 (0.83) a 4.33 (0.86) a 
Triglycerides (mmol/l) 0.82 (0.28) 0.88 (0.29) 1.25 (0.73) a 1.68 (1.55) a 
Systolic BP (mmHg) 113 (12.3) 117 (12.0) a 118 (13.6) a 123 (14.0) a 
Diastolic BP (mmHg) 70.3 (8.90) 73.9 (9.78) a 73.7 (10.3) a 78.5 (10.4) a 
Hs-C-reactive protein (mg/l) 1.09 (1.78) 2.23 (4.47) a 1.37 (2.03) a 1.77 (2.26) a 
Glucose (mmol/l) 4.99 (0.34) 5.64 (0.47) a 5.08 (0.33) a 5.71 (0.41) a 
HbA1c (%) 5.29 (0.18) 5.58 (0.28) a 5.35 (0.17) a 5.63 (0.26) a 
HbA1c (mmol/l) 34.4 (2.00) 37.4 (2.95) a 35.0 (1.92) a 38.0 (2.76) a 
Insulin (mU/l) 5.73 (3.40) 8.68 (6.04) a 7.59 (5.05) a 11.0 (7.43) a 
Body mass index (kg/m2) 23.6 (3.39) 26.2 (4.90) a 25.6 (3.99) a 28.3 (4.75) a 
Waist circumference (cm) 82.5 (10.2) 90.4 (14.3) a 88.9 (11.9) a 97.7 (12.8) a 
Daily smokers (%) 7.81 17.7 a 13.2 a 16.2 a 
     
 CNC  PRNC CHC PRHC 
Number of subjects 362 127 480 247 
Age (years) 39.9 (4.79) 40.9 (4.87) 41.8 (5.07)b 42.8 (4.99)b 
Males (%) 28.7 48.0b 42.5b 63.6b 
Total cholesterol (mmol/l) 4.36 (0.51) 4.39 (0.53) 5.64 (0.73)b 5.75 (0.78)b 
LDL cholesterol (mmol/l) 2.52 (0.35) 2.53 (0.38) 3.75 (0.64)b 3.84 (0.67)b 
HDL cholesterol (mmol/l) 1.41 (0.34) 1.29 (0.34)b 1.38 (0.32) 1.29 (0.29)b 
Non-HDL cholesterol (mmol/l) 2.95 (0.42) 3.10 (0.52)b 4.27 (0.72)b 4.47 (0.78)b 
Triglycerides (mmol/l) 0.97 (0.50) 1.27 (0.77)b 1.15 (0.54)b 1.39 (0.62)b 
Systolic BP (mmHg) 114 (12.2) 119 (12.3)b 118 (13.9)b 123 (14.4)b 
Diastolic BP (mmHg) 71.3 (9.61) 75.3 (10.0)b 73.6 (10.2)b 78.5 (10.6)b 
Hs-C-reactive protein (mg/l) 1.39 (2.27) 2.06 (3.74) 1.19 (1.72) 1.80 (2.34)b 
Glucose (mmol/l) 5.01 (0.35) 5.70 (0.48)b 5.08 (0.32)b 5.69 (0.40)b 
HbA1c (%) 5.31 (0.18) 5.58 (0.26)b 5.36 (0.18)b 5.64 (0.25)b 
HbA1c (mmol/l) 34.5 (1.95) 37.4 (2.86)b 35.1 (1.95)b 38.2 (2.69)b 
Insulin (mU/l) 6.50 (4.42) 10.3 (7.48)b 7.21 (4.49)b 9.99 (6.13)b 
Body mass index (kg/m2) 24.1 (3.87) 27.3 (5.23)b 25.6 (3.85)b 28.1 (4.69)b 
Waist circumference (cm) 84.1 (10.9) 94.1 (14.8)b 88.9 (11.9)b 96.8 (12.6)b 
Daily smokers (%) 11.3 20.5b 11.4 14.6 
Definitions/Abbreviations:  PR0, prediabetes without dyslipidaemia; PRD, prediabetes with 
dyslipidaemia; CD, non-prediabetic subjects with dyslipidaemia; C0, healthy subjects without 
prediabetes or dyslipidaemia; : PRNC, prediabetes without hyper-LDL cholesterolaemia; PRHC, 
prediabetes with hyper-LDL cholesterolaemia; CHC, non-prediabetic subjects with hyper-LDL 
cholesterolaemia; CNC, healthy subjects without prediabetes or hyper-LDL cholesterolaemia; Hs, 
High sensitive. 
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Statistics: t-test or χ2 test when appropriate. Values are mean (±SD) or proportions. a Difference as 
compared to C0, p<0.05. 
b Difference as compared to CNC, p<0.05 
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Table 2. Pathways enriched in all prediabetic subjects (PR) in comparison to all control subjects 
without prediabetes (C). All pathways were up-regulated as indicated by a positive NES. 
 NES Enrichment p-value FDR FWER 
Model 1     
Steroid biosynthesisa 2.13 <0.001 0.008 0.006 
Cholesterol biosynthesisb 2.04 <0.001 0.007 0.009 
Superpathway of cholesterol 
biosynthesisb 
1.91 <0.001 0.009 0.034 
Superpathway of methionine 
degradationb 
1.97 0.002 0.006 0.019 
     
Model 2     
Steroid biosynthesisa 2.06 0.002 0.010 0.010 
Cholesterol biosynthesisb 1.99 <0.001 0.005 0.007 
Superpathway of methionine 
degradationb 
1.97 0.002 0.015 0.045 
     
Model 3     
Steroid biosynthesisa 2.06 <0.001 0.014 0.012 
Cholesterol biosynthesisb 2.00 <0.001 0.003 0.006 
Statistics: Model 1: Gene set enrichment analysis adjusted for age, sex, BMI and the first 7 PCs; 
Model 2: Model 1 + additionally adjusted for waist circumference (instead of BMI), systolic and 
diastolic BP, smoking and insulin; Model 3: Model 2 + additionally adjusted for Hs-CRP. a KEGG 
pathways, b HumanCyc pathways. Abbreviations: FDR, false discovery rate; FWER, family-wise 
error rate; NES, normalized enrichment score; PC, principal component; Hs, High sensitive. 
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Table 3. Pathways enriched in prediabetic subjects without dyslipidaemia (PR0) in comparison to 
control subjects without prediabetes and dyslipidaemia (C0). All pathways were up-regulated as 
indicated by a positive NES. 
 NES Enrichment p-value FDR FWER 
Model 1     
Steroid biosynthesisa 2.04 <0.001 0.020 0.022 
Cholesterol biosynthesisb 2.10 <0.001 0.001 0.001 
Superpathway of cholesterol 
biosynthesisb 
1.94 0.002 0.007 0.015 
Downstream signalling in naïve 
CD8+ T cellsc 
1.99 <0.001 0.020 0.038 
IL12-mediated signalling 
eventsc 
2.00 0.002 0.035 0.036 
     
Model 2     
Steroid biosynthesisa 1.96 <0.001 0.048 0.044 
Cholesterol biosynthesisb 1.97 <0.001 0.009 0.015 
Downstream signalling in naïve 
CD8+ T cellsc 
2.09 0.002 0.006 0.007 
IL12-mediated signalling 
eventsc 
1.99 0.002 0.014 0.030 
     
Model 3     
Downstream signalling in naïve 
CD8+ T cellsc 
2.08 <0.001 0.016 0.012 
IL12-mediated signalling 
eventsc 
2.06 <0.001 0.011 0.022 
Statistics: Model 1: Gene set enrichment analysis adjusted for age, sex, BMI and the first 7 PCs; 
Model 2: Model 1 + additionally adjusted for waist circumference (instead of BMI), systolic and 
diastolic BP, smoking and insulin; Model 3: Model 2 + additionally adjusted for Hs-CRP. a KEGG 
pathways, b HumanCyc pathways, and c NCI PID pathways. Abbreviations: FDR, false discovery 
rate; FWER, family-wise error rate; NES, normalized enrichment score; PC, principal component; 
Hs, high sensitive. 
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Table 4. Pathways enriched in subjects who had prediabetes but no hyper-LDL cholesterolaemia 
(PRNC) in comparison to those without prediabetes and hyper-LDL cholesterolaemia (CNC) (LDL ≤ 
3.0 mmol/l). All pathways were up-regulated as indicated by a positive NES. 
 NES Enrichment p-value FDR FWER 
Model 1     
Superpathway of cholesterol 
biosynthesisa 
1.92 0.002 0.052 0.030 
     
Model 2     
Superpathway of cholesterol 
biosynthesisa 
1.87 0.002 0.054 0.042 
     
Model 3     
Superpathway of cholesterol 
biosynthesisa 
1.96 <0.001 0.015 0.012 
Statistics: Model 1: Gene set enrichment analysis adjusted for age, sex, BMI and the first 7 PCs; 
Model 2: Model 1 + additionally adjusted for waist circumference (instead of BMI), systolic and 
diastolic BP, smoking and insulin; Model 3: Model 2 + additionally adjusted for Hs-CRP. a 
HumanCyc pathways. Abbreviations: FDR, false discovery rate; FWER, family-wise error rate; 
NES, normalized enrichment score; PC, principal component; Hs, high sensitive.  
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Figure 1. Gene expression changes of (a) NTRK1, (b) GZMB, (c) PRF1, (d) KIR2DL3, (e) 
FAM179A and (f) SLPI genes over prediabetes and control phenotypes. 
 
 
